The Relationship Between Total Sialic Acid and Superoxide Dismutase and the Diagnosis and Prognosis of Lipoid Pneumonia

Launched by HU YINAN · May 21, 2024

Keywords

ClinConnect Summary

This is an observational study (looking back at medical records) that wants to see if two biomarkers, total sialic acid (TSA) and the enzyme superoxide dismutase (SOD), can help diagnose lipid pneumonia and predict how patients do over time. Researchers will compare people with lipid pneumonia to people with other lung conditions, such as bacterial or fungal pneumonia and other related diseases. The main goal is to find out if SOD levels at the time of hospital admission can help diagnose lipid pneumonia, and whether TSA levels are also useful, along with outcomes like death within about 10 years after discharge and a blood test called neutrophil-to-lymphocyte ratio.

Adults 18 and older who have one of the study’s included lung conditions and have biopsy or special staining confirming lipid pneumonia (or the other conditions listed) may be eligible. Exclusions include being under 18, having only a history of oil exposure without pathology, COVID-19 at illness onset, or pregnancy. The study is enrolling about 160 participants at China-Japan Friendship Hospital in Beijing and is currently inviting eligible people. Participants will complete online surveys about symptoms, oxygen status, and lung scans, and researchers will collect baseline information from medical records (demographics, smoking, lung tests, imaging, treatments, and initial SOD/TSA levels). This is not a drug trial, and results are not yet available. Data may be shared with other researchers in the future, and the study is overseen by the hospital with no FDA-regulated drugs involved.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age≥ 18 years old;
• • 2. The diagnosis of lipoid pneumonia must be supported by lung biopsy pathological support or positive oil red O or Sudan staining in bronchoalveolar lavage fluid;
• • 3. Patients with bacterial and fungal pneumonia must be supported by etiological evidence;
• • 4. Patients with cryptogenic organizing pneumonia and pulmonary alveolar proteinosis must be supported by lung biopsy pathology;
• • 5. Patients with lung mucinous adenocarcinoma must be supported by lung tissue biopsy;
• • 6. Lung imaging of patients with pulmonary edema must show paving stone signs;
• Exclusion Criteria:
• • 1. Age\< 18 years old;
• • 2. The patient only has a history of lipid inhalation and no pathology or positive lipoid staining;
• • 3. Co-infection with the corona virus disease 2019 at the onset of illness;
• • 4. Pregnant